» Articles » PMID: 11919160

Rationale for the Role of Osteoclast-like Cells in Arterial Calcification

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2002 Mar 29
PMID 11919160
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerotic arteries frequently become calcified, and these calcium deposits are associated with a high risk of adverse clinical events. Descriptive studies suggest calcification is an organized and regulated process with many similarities to osteogenesis, yet the mechanism and its relationship to atherosclerosis remain largely unknown. In bone development and homeostasis, mineral deposition by osteoblasts and mineral resorption by osteoclasts are delicately balanced such that there is no overall gain or loss in bone mass. We hypothesize that there exists in arteries a mechanism that similarly balances mineral deposition with resorption. We propose that the cellular mediators of arterial mineral resorption are osteoclast-like cells (OLCs) derived from hematopoietic precursors of the mononuclear phagocytic lineage. In arterial microenvironments, mononuclear precursors are induced to differentiate toward OLCs by macrophage-colony stimulating factor and receptor activator of NF-kappaB ligand, both of which are necessary and sufficient for osteoclastogenesis and mineral resorption in bone. OLCs may participate in normal mineral homeostasis within the arterial wall or, alternatively, may be recruited to specific sites within developing plaque. Net calcium deposition occurs as a result of focal perturbation of the balance between the activity of osteoblast-like cells and OLCs. Our proposed mechanism thus views arterial mineral deposition not so much as an active pathological process, but as a localized failure of protective mechanisms that actively oppose mineral deposition within the disordered metabolic milieu of developing atherosclerotic plaque.

Citing Articles

Engineered osteoclasts as living treatment materials for heterotopic ossification therapy.

Jin W, Lin X, Pan H, Zhao C, Qiu P, Zhao R Nat Commun. 2021; 12(1):6327.

PMID: 34732696 PMC: 8566554. DOI: 10.1038/s41467-021-26593-1.


Transcriptional Programming in Arteriosclerotic Disease: A Multifaceted Function of the Runx2 (Runt-Related Transcription Factor 2).

Chen Y, Zhao X, Wu H Arterioscler Thromb Vasc Biol. 2020; 41(1):20-34.

PMID: 33115268 PMC: 7770073. DOI: 10.1161/ATVBAHA.120.313791.


Ferryl Hemoglobin Inhibits Osteoclastic Differentiation of Macrophages in Hemorrhaged Atherosclerotic Plaques.

Zavaczki E, Gall T, Zarjou A, Hendrik Z, Potor L, Toth C Oxid Med Cell Longev. 2020; 2020:3721383.

PMID: 32184915 PMC: 7063196. DOI: 10.1155/2020/3721383.


The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis.

da Silveira W, Vazquez-Hidalgo E, Bartolotta E, Renaud L, Paolini P, Hardiman G Pharmacogenomics. 2019; 20(16):1125-1141.

PMID: 31755367 PMC: 7026769. DOI: 10.2217/pgs-2019-0077.


Genetics of Subclinical Coronary Atherosclerosis.

Bielak L, Peyser P Curr Genet Med Rep. 2019; 6(3):116-123.

PMID: 30854262 PMC: 6405218. DOI: 10.1007/s40142-018-0145-x.